Induction of protective effector immunity to prevent pathogenesis caused by the respiratory syncytial virus. Implications on therapy and vaccine design

Immunology

Volumn 143, Issue 1, 2014, Pages 1-12

  Espinoza, Janyra A ^a   Bueno, Susan M ^a,b   Riedel, Claudia A ^c   Kalergis, Alexis M ^a,b,d  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b INSER MUMR 1064   (France)

^c Pontificia Universidad Católica de Chile   (Chile)

^d PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

HRSV; Lung; T helper type 1 type 2 cells; Vaccination; Viral

Indexed keywords

1 (2,3 DIHYDRO 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (2 FLUOROPHENYL)UREA; 1 CYCLOPROPYL 1,3 DIHYDRO 3 [[1 (4 HYDROXYBUTYL) 1H BENZIMIDAZOL 2 YL]METHYL] 2H IMIDAZO[4,5 C]PYRIDIN 2 ONE; 2 [[2 [[1 (2 AMINOETHYL) 4 PIPERIDINYL]AMINO] 4 METHYL 1H BENZIMIDAZOL 1 YL]METHYL] 6 METHYL 3 PYRIDINOL; ALVESPIMYCIN; ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; ASVASIRAN; BACTERIAL VECTOR; BCG VACCINE; DNA VACCINE; GOLD NANOPARTICLE; HR 121; HR 212; LIVE VACCINE; MOTAVIZUMAB; OLIGOMER; PALIVIZUMAB; PEPTIDE DERIVATIVE; PHOSPHORODIAMIDATEMORPHOLINO OLIGOMER; RESPIRATORY SYNCYTIAL VIRUS VACCINE; RFI 641; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; RIBAVIRIN; SILVER NANOPARTICLE; SMALL INTERFERING RNA; SUBUNIT VACCINE; T 118; TANESPIMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS VECTOR;

ADAPTIVE IMMUNITY; ANTIVIRAL ACTIVITY; ARTICLE; CENTRAL NERVOUS SYSTEM INFECTION; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOLOGICAL MEMORY; INNATE IMMUNITY; LIFE CYCLE; LUNG INJURY; MYCOBACTERIUM BOVIS BCG; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; PASSIVE IMMUNIZATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECURRENT INFECTION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RESPIRATORY TRACT INFLAMMATION; TH2 CELL; VIRAL CLEARANCE; VIRAL RESPIRATORY TRACT INFECTION; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS VIRULENCE;

HRSV; LUNG; T HELPER TYPE 1/TYPE 2 CELLS; VACCINATION; VIRAL;

HUMANS; LUNG; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYSTEM;

EID: 84904906376     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12313     Document Type: Article

References (98)

1. Blount RE Jr, Morris JA, Savage RE. Recovery of cytopathogenic agent from chimpanzees with coryza. Proc Soc Exp Biol Med 1956; 92:544-9.
2. Beem M, Wright FH, Hamre D, Egerer R, Oehme M. Association of the chimpanzee coryza agent with acute respiratory disease in children. N Engl J Med 1960; 263:523-30.
3. Chanock R, Finberg L. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). II. Epidemiologic aspects of infection in infants and young children. Am J Hyg 1957; 66:291-300.
4. Hall CB, Weinberg GA, Iwane MK et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009; 360:588-98.
5. Nair H, Brooks WA, Katz M et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet 2010; 378:1917-30.
6. Baker KA, Ryan ME. RSV infection in infants and young children. What's new in diagnosis, treatment, and prevention? Postgrad Med 1999; 106:97-9, 103-4, 7-8 passim.
7. Henderson FW, Collier AM, Clyde WA Jr, Denny FW. Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N Engl J Med 1979; 300:530-4.
8. Gonzalez PA, Bueno SM, Carreno LJ, Riedel CA, Kalergis AM. Respiratory syncytial virus infection and immunity. Rev Med Virol 2012; 22:230-44.
9. Aujard Y, Fauroux B. Risk factors for severe respiratory syncytial virus infection in infants. Respir Med 2002; 96(Suppl. B):S9-14.
10. Hall CB, Simoes EA, Anderson LJ. Clinical and epidemiologic features of respiratory syncytial virus. Curr Top Microbiol Immunol 372:39-57.
11. Falsey AR. Respiratory syncytial virus infection in adults. Semin Respir Crit Care Med 2007; 28:171-81.
12. Respiratory syncytial virus infection: admissions to hospital in industrial, urban, and rural areas. Report to the Medical Research Council Subcommittee on Respiratory Syncytial Virus Vaccines. Br Med J 1978; 2:796-8.
13. Collins PL, Melero JA. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res 2011; 162:80-99.
14. Tan L, Coenjaerts FE, Houspie L, Viveen MC, van Bleek GM, Wiertz EJ, Martin DP, Lemey P. The comparative genomics of human respiratory syncytial virus subgroups A and B: genetic variability and molecular evolutionary dynamics. J Virol 87:8213-26.
15. Gonzalez PA, Carreno LJ, Bueno SM, Riedel CA, Kalergis AM. Understanding respiratory syncytial virus infection to improve treatment and immunity. Curr Mol Med 2013; 13:1122-39.
16. Rodriguez R, Ramilo O. Respiratory syncytial virus: how, why and what to do. J Infect 2014; 68(Suppl. 1):S115-8.
17. Shaikh FY, Utley TJ, Craven RE, Rogers MC, Lapierre LA, Goldenring JR, Crowe JE Jr. Respiratory syncytial virus assembles into structured filamentous virion particles independently of host cytoskeleton and related proteins. PLoS One 2012; 7:e40826.
18. Batonick M, Wertz GW. Requirements for human respiratory syncytial virus glycoproteins in assembly and egress from infected cells. Adv Virol 2011; 2011: Article ID: 343408.
19. Bueno SM, Gonzalez PA, Pacheco R et al. Host immunity during RSV pathogenesis. Int Immunopharmacol 2008; 8:1320-9.
20. White LJ, Mandl JN, Gomes MG et al. Understanding the transmission dynamics of respiratory syncytial virus using multiple time series and nested models. Math Biosci 2007; 209:222-39.
21. Hall CB, Douglas RG Jr, Schnabel KC, Geiman JM. Infectivity of respiratory syncytial virus by various routes of inoculation. Infect Immun 1981; 33:779-83.
22. La Rosa G, Fratini M, Della Libera S, Iaconelli M, Muscillo M. Viral infections acquired indoors through airborne, droplet or contact transmission. Ann Ist Super Sanita 2013; 49:124-32.
23. Gralton J, Tovey ER, McLaws ML, Rawlinson WD. Respiratory virus RNA is detectable in airborne and droplet particles. J Med Virol 2013; 85:2151-9.
24. Imaz MS, Sequeira MD, Videla C, Veronessi I, Cociglio R, Zerbini E, Carballal G. Clinical and epidemiologic characteristics of respiratory syncytial virus subgroups A and B infections in Santa Fe, Argentina. J Med Virol 2000; 61:76-80.
25. Lotz MT, Peebles RS Jr. Mechanisms of respiratory syncytial virus modulation of airway immune responses. Curr Allergy Asthma Rep 2012; 12:380-7.
26. Gomez RS, Mora JE, Cortes CM, Riedel CA, Ferres M, Bueno SM, Kalergis AM. Respiratory syncytial virus detection in cells and clinical samples by using three new monoclonal antibodies. J Med Virol 2013; 86:1256-66.
27. Lindquist ME, Mainou BA, Dermody TS, Crowe JE Jr. Activation of protein kinase R is required for induction of stress granules by respiratory syncytial virus but dispensable for viral replication. Virology 2011; 413:103-10.
28. Ghildyal R, Ho A, Dias M, Soegiyono L, Bardin PG, Tran KC, Teng MN, Jans DA. The respiratory syncytial virus matrix protein possesses a Crm1-mediated nuclear export mechanism. J Virol 2009; 83:5353-62.
29. Zeng R, Cui Y, Hai Y, Liu Y. Pattern recognition receptors for respiratory syncytial virus infection and design of vaccines. Virus Res 2011; 167:138-45.
30. Satkunanathan S, Kumar N, Bajorek M, Purbhoo MA, Culley FJ. Respiratory syncytial virus infection, TLR3 ligands, and proinflammatory cytokines induce CD161 ligand LLT1 expression on the respiratory epithelium. J Virol 2014; 88:2366-73.
31. Murawski MR, Bowen GN, Cerny AM, Anderson LJ, Haynes LM, Tripp RA, Kurt-Jones EA, Finberg RW. Respiratory syncytial virus activates innate immunity through Toll-like receptor 2. J Virol 2009; 83:1492-500.
32. Haynes LM, Moore DD, Kurt-Jones EA, Finberg RW, Anderson LJ, Tripp RA. Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus. J Virol 2001; 75:10730-7.
33. Piedimonte G. Pathophysiological mechanisms for the respiratory syncytial virus-reactive airway disease link. Respir Res 2002; 3(Suppl. 1):S21-5.
34. Segovia J, Sabbah A, Mgbemena V et al. TLR2/MyD88/NF-κB pathway, reactive oxygen species, potassium efflux activates NLRP3/ASC inflammasome during respiratory syncytial virus infection. PLoS One 2012; 7:e29695.
35. van Drunen Littel-van den Hurk S, Watkiss ER. Pathogenesis of respiratory syncytial virus. Curr Opin Virol 2012; 2:300-5.
36. Gonzalez PA, Prado CE, Leiva ED, Carreno LJ, Bueno SM, Riedel CA, Kalergis AM. Respiratory syncytial virus impairs T cell activation by preventing synapse assembly with dendritic cells. Proc Natl Acad Sci USA 2008; 105:14999-5004.
37. Tsutsumi H, Kojima T, Hirakawa S et al. Respiratory syncytial virus infection and the tight junctions of nasal epithelial cells. Adv Otorhinolaryngol 2011; 72:153-6.
38. Gonzalez PA, Bueno SM, Riedel CA, Kalergis AM. Impairment of T cell immunity by the respiratory syncytial virus: targeting virulence mechanisms for therapy and prophylaxis. Curr Med Chem 2009; 16:4609-25.
39. Bueno SM, Gonzalez PA, Riedel CA, Carreno LJ, Vasquez AE, Kalergis AM. Local cytokine response upon respiratory syncytial virus infection. Immunol Lett 2011; 136:122-9.
40. Chirkova T, Boyoglu-Barnum S, Gaston KA, Malik FM, Trau SP, Oomens AG, Anderson LJ. Respiratory syncytial virus G protein CX3C motif impairs human airway epithelial and immune cell responses. J Virol 2013; 87:13466-79.
41. Bera MM, Lu B, Martin TR, Cui S, Rhein LM, Gerard C, Gerard NP. Th17 cytokines are critical for respiratory syncytial virus-associated airway hyperreponsiveness through regulation by complement C3a and tachykinins. J Immunol 2011; 187:4245-55.
42. Wang H, Su Z, Schwarze J. Healthy but not RSV-infected lung epithelial cells profoundly inhibit T cell activation. Thorax 2009; 64:283-90.
43. Qin L, Hu CP, Feng JT, Xia Q. Activation of lymphocytes induced by bronchial epithelial cells with prolonged RSV infection. PLoS One 2011; 6:e27113.
44. Walsh EE, Falsey AR. Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults. J Infect Dis 2004; 190:373-8.
45. Singleton R, Etchart N, Hou S, Hyland L. Inability to evoke a long-lasting protective immune response to respiratory syncytial virus infection in mice correlates with ineffective nasal antibody responses. J Virol 2003; 77:11303-11.
46. Lee HC, Headley MB, Loo YM, Berlin A, Gale M Jr, Debley JS, Lukacs NW, Ziegler SF. Thymic stromal lymphopoietin is induced by respiratory syncytial virus-infected airway epithelial cells and promotes a type 2 response to infection. J Allergy Clin Immunol 2012; 130:1187-96 e5.
47. Lay MK, Gonzalez PA, Leon MA, Cespedes PF, Bueno SM, Riedel CA, Kalergis AM. Advances in understanding respiratory syncytial virus infection in airway epithelial cells and consequential effects on the immune response. Microbes Infect 2013; 15:230-42.
48. Gonzalez PA, Carreno LJ, Figueroa CA, Kalergis AM. Modulation of immunological synapse by membrane-bound and soluble ligands. Cytokine Growth Factor Rev 2007; 18:19-31.
49. Carreno LJ, Gonzalez PA, Bueno SM, Riedel CA, Kalergis AM. Modulation of the dendritic cell-T-cell synapse to promote pathogen immunity and prevent autoimmunity. Immunotherapy 2011; 3:6-11.
50. Domachowske JB, Rosenberg HF. Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment. Clin Microbiol Rev 1999; 12:298-309.
51. Ogra PL. Respiratory syncytial virus: the virus, the disease and the immune response. Paediatr Respir Rev 2004; 5(Suppl. A):S119-26.
52. Martinez FD. Respiratory syncytial virus bronchiolitis and the pathogenesis of childhood asthma. Pediatr Infect Dis J 2003; 22:S76-82.
53. Eisenhut M. Extrapulmonary manifestations of severe RSV bronchiolitis. Lancet 2006; 368:988.
54. Eisenhut M. Cerebral involvement in respiratory syncytial virus disease. Brain Dev 2007; 29:454.
55. Espinoza JA, Bohmwald K, Cespedes PF et al. Impaired learning resulting from respiratory syncytial virus infection. Proc Natl Acad Sci USA 2013; 110:9112-7.
56. Bawage SS, Tiwari PM, Pillai S, Dennis V, Singh SR. Recent advances in diagnosis, prevention, and treatment of human respiratory syncytial virus. Adv Virol 2013; 2013:595768.
57. Rodriguez WJ, Parrott RH. Ribavirin aerosol treatment of serious respiratory syncytial virus infection in infants. Infect Dis Clin North Am 1987; 1:425-39.
58. Chapman J, Abbott E, Alber DG et al. RSV604, a novel inhibitor of respiratory syncytial virus replication. Antimicrob Agents Chemother 2007; 51:3346-53.
59. Geller R, Andino R, Frydman J. Hsp90 inhibitors exhibit resistance-free antiviral activity against respiratory syncytial virus. PLoS One 2013; 8:e56762.
60. Sun Z, Pan Y, Jiang S, Lu L. Respiratory syncytial virus entry inhibitors targeting the F protein. Viruses 2013; 5:211-25.
61. Budge PJ, Lebowitz J, Graham BS. Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers. Antimicrob Agents Chemother 2003; 47:3470-7.
62. Wyde PR, Chetty SN, Jewell AM, Boivin G, Piedra PA. Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro. Antiviral Res 2003; 60:51-9.
63. Cianci C, Meanwell N, Krystal M. Antiviral activity and molecular mechanism of an orally active respiratory syncytial virus fusion inhibitor. J Antimicrob Chemother 2005; 55:289-92.
64. Cianci C, Yu KL, Combrink K et al. Orally active fusion inhibitor of respiratory syncytial virus. Antimicrob Agents Chemother 2004; 48:413-22.
65. Huntley CC, Weiss WJ, Gazumyan A et al. RFI-641, a potent respiratory syncytial virus inhibitor. Antimicrob Agents Chemother 2002; 46:841-7.
66. Stone JW, Thornburg NJ, Blum DL, Kuhn SJ, Wright DW, Crowe JE Jr. Gold nanorod vaccine for respiratory syncytial virus. Nanotechnology 2013; 24:295102.
67. Quan FS, Kim Y, Lee S, Yi H, Kang SM, Bozja J, Moore ML, Compans RW. Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice. J Infect Dis 2011; 204:987-95.
68. Jairath S, Vargas PB, Hamlin HA, Field AK, Kilkuskie RE. Inhibition of respiratory syncytial virus replication by antisense oligodeoxyribonucleotides. Antiviral Res 1997; 33:201-13.
69. Bitko V, Musiyenko A, Shulyayeva O, Barik S. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 2005; 11:50-5.
70. Vig K, Lewis N, Moore EG, Pillai S, Dennis VA, Singh SR. Secondary RNA structure and its role in RNA interference to silence the respiratory syncytial virus fusion protein gene. Mol Biotechnol 2009; 43:200-11.
71. Zhang W, Yang H, Kong X et al. Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat Med 2005; 11:56-62.
72. DeVincenzo J, Cehelsky JE, Alvarez R et al. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res 2008; 77:225-31.
73. Alvarez R, Elbashir S, Borland T et al. RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy. Antimicrob Agents Chemother 2009; 53:3952-62.
74. Zamora MR, Budev M, Rolfe M et al. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am J Respir Crit Care Med 2011; 183:531-8.
75. Ripple MJ, You D, Honnegowda S, Giaimo JD, Sewell AB, Becnel DM, Cormier SA. Immunomodulation with IL-4Rα antisense oligonucleotide prevents respiratory syncytial virus-mediated pulmonary disease. J Immunol 2010; 185:4804-11.
76. Lai SH, Stein DA, Guerrero-Plata A et al. Inhibition of respiratory syncytial virus infections with morpholino oligomers in cell cultures and in mice. Mol Ther 2008; 16:1120-8.
77. Bonfanti JF, Meyer C, Doublet F et al. Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121). J Med Chem 2008; 51:875-96.
78. Monoclonal antibody approved for RSV disease prevention. Am J Health Syst Pharm 1998; 55:1654, 6.
79. Welliver RC. Respiratory syncytial virus immunoglobulin and monoclonal antibodies in the prevention and treatment of respiratory syncytial virus infection. Semin Perinatol 1998; 22:87-95.
80. Palivizumab (Synagis) for prevention of RSV infection. Med Lett Drugs Ther 1999; 41:3-4.
81. Fisher RG, Johnson JE, Dillon SB, Parker RA, Graham BS. Prophylaxis with respiratory syncytial virus F-specific humanized monoclonal antibody delays and moderately suppresses the native antibody response but does not impair immunity to late rechallenge. J Infect Dis 1999; 180:708-13.
82. Wu H, Pfarr DS, Losonsky GA, Kiener PA. Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab. Curr Top Microbiol Immunol 2008; 317:103-23.
83. Mejias A, Chavez-Bueno S, Raynor MB, Connolly J, Kiener PA, Jafri HS, Ramilo O. Motavizumab, a neutralizing anti-Respiratory Syncytial Virus (RSV) monoclonal antibody significantly modifies the local and systemic cytokine responses induced by RSV in the mouse model. Virol J 2007; 4:109.
84. Mejias A, Chavez-Bueno S, Rios AM et al. Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency. Antimicrob Agents Chemother 2005; 49:4700-7.
85. Lenney W. RSV disease-is there a role for prevention? Respir Med 2001; 95:170-2.
86. Li X, Sambhara S, Li CX et al. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate. Virology 2000; 269:54-65.
87. Martinez-Sobrido L, Gitiban N, Fernandez-Sesma A et al. Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector. J Virol 2006; 80:1130-9.
88. Wu H, Dennis VA, Pillai SR, Singh SR. RSV fusion (F) protein DNA vaccine provides partial protection against viral infection. Virus Res 2009; 145:39-47.
89. Cautivo KM, Bueno SM, Cortes CM, Wozniak A, Riedel CA, Kalergis AM. Efficient lung recruitment of respiratory syncytial virus-specific Th1 cells induced by recombinant bacillus Calmette-Guérin promotes virus clearance and protects from infection. J Immunol 2010; 185:7633-45.
90. Bueno SM, Gonzalez PA, Cautivo KM et al. Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG. Proc Natl Acad Sci USA 2008; 105:20822-7.
91. Xie C, He JS, Zhang M et al. Oral respiratory syncytial virus (RSV) DNA vaccine expressing RSV F protein delivered by attenuated Salmonella typhimurium. Hum Gene Ther 2007; 18:746-52.
92. Mok H, Lee S, Utley TJ et al. Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats. J Virol 2007; 81:13710-22.
93. Subbarayan P, Qin H, Pillai S et al. Expression and characterization of a multivalent human respiratory syncytial virus protein. Mol Biol 2010; 44:477-87.
94. Rigter A, Widjaja I, Versantvoort H et al. A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles. PLoS One 2013; 8:e71072.
95. Kaaijk P, Luytjes W, Rots NY. Vaccination against RSV: is maternal vaccination a good alternative to other approaches? Hum Vaccin Immunother 2013; 9:1263-7.
96. Munoz FM, Piedra PA, Glezen WP. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine 2003; 21:3465-7.
97. Englund JA. Passive protection against respiratory syncytial virus disease in infants: the role of maternal antibody. Pediatr Infect Dis J 1994; 13:449-53.
98. Blanchard-Rohner G, Meier S, Bel M, Combescure C, Othenin-Girard V, Swali RA, Martinez de Tejada B, Siegrist CA. Influenza vaccination given at least 2 weeks before delivery to pregnant women facilitates transmission of seroprotective influenza-specific antibodies to the newborn. Pediatr Infect Dis J 2013; 32:1374-80.